Nasopharyngeal Bacterial Microbiota Composition and SARS-CoV-2 IgG Antibody Maintenance in Asymptomatic/Paucisymptomatic Subjects무증상/무증상 피험자의 비인두 세균성 미생물총 구성 및 SARS-CoV-2 IgG 항체 유지 관리Article Published on 2022-07-062022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adaptive immune response Analysis anti-RBD antibody Asymptomatic Asymptomatic carriers Bacterial best cause characterized condition coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 enrolment Evidence IgG antibody immune response immunoglobulins Immunological memory Infection influence investigated knowledge Lung injury maintenance mechanism microbiota multi-organ failure nasopharyngeal nasopharyngeal bacterial microbiota. Nasopharyngeal swab Odds ratio performed positive positive serology predict Regulation respiratory respiratory infection respiratory infections SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 infections SARS-CoV-2 RNA serum severe acute respiratory syndrome Coronavirus severity subject tested UNICORN Viral viral entry viral infections [DOI] 10.3389/fcimb.2022.882302 PMC 바로가기 [Article Type] Article
Omicron infection enhances Delta antibody immunity in vaccinated personsOmicron 감염은 예방 접종을 받은 사람의 Delta 항체 면역을 향상시킵니다.Article Published on 2022-07-012022-09-11 Journal: Nature [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] absolute levels acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody immunity B.1.617.2 Beta BNT162b2 breakthrough infections coronavirus cross-protection Delta develop dominant elicit ENhance enrolment focus Follow-up follow-up time geometric geometric mean Immunity individual Infection interquartile range Johnson & Johnson median moderate neutralization neutralization capacity neutralization test neutralizing immunity offer omicron other variants participant Participants Pfizer Protective reduction respiratory severe acute respiratory syndrome Coronavirus South Africa Symptom symptom onset titre vaccinated individual vaccinated individuals vaccination variant variants virus Virus neutralization viruses [DOI] 10.1038/s41586-022-04830-x PMC 바로가기 [Article Type] Article
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]건강한 개인에서 다양한 COVID-19 백신 조합의 안전성 및 면역원성 평가: 무작위, 피험자 맹검, 대조 3상 시험을 위한 연구 프로토콜 [PRIBIVAC]Article Published on 2022-06-162022-09-11 Journal: Trials [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 antibodies antibody approval best blood sample Blood samples BNT162b2 boost booster booster dose booster vaccinations cellular Cellular immune response collected Combination Comprehensive control arm Controlled clinical trial CoronaVac country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstration different time point different time points dose Effectiveness Eligible participants Endpoint enrolment evade excluded group healthy Heterologous homologous host immunity humoral immune immune profiling immune response Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Infection Intervention intervention arm Laboratory test Laboratory tests Local maintain mRNA mRNA vaccine mRNA-1273 omicron over parameters participant performed persistence phase Phase 3 phase 3 trial physical population immunity pregnant primary endpoint Probability quantity raising randomization Randomized Randomized controlled trial regimen Regulatory SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Singapore Study protocol vaccination Vaccine vaccine availability vaccine booster vaccine candidate variants variants of concern volunteers wildtype [DOI] 10.1186/s13063-022-06345-2 PMC 바로가기 [Article Type] Article
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trialClinical Trial Published on 2022-06-072022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료법, 치료제, [키워드] 1:1 95% CI administration Adverse age Antigen assigned AstraZeneca block sizes blocked clinical clinical evaluation clinically collected conducted Course COVID-19 COVID-19 vaccination death dose double-blind Efficacy enrolled enrolment Europe evaluate event Fever finding for inclusion funding individual intramuscular intramuscular injections investigators involved Japan laboratory-confirmed SARS-CoV-2 infection Latin America less Mild moderate Moderate COVID-19 monoclonal antibody combination non-hospitalised occurred Older outcomes participant Phase 3 Placebo placebo-controlled study placebo-controlled trial prevent disease progression primary endpoint progression provided randomisation randomised Randomly receive Registered required respiratory tract risk reduction RT-PCR scale severe COVID-19 severity specimen Sponsor statistically stratified study drug Symptom symptom onset the disease the placebo group treating Treatment treatment group USA WHO [DOI] 10.1016/S2213-2600(22)00180-1 [Article Type] Clinical Trial
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI TrialRandomized Controlled Trial Published on 2022-06-012022-10-05 Journal: Advances in therapy [Category] COVID19(2023년), SARS, 임상, [키워드] breath clearance clinical status COVID-19 double-blind Dyspnoea ELOM-080 enhancement enhancer enrolment EudraCT evaluated exploratory exploratory study had no hospitalisation hospitalised IMPROVE Inflammatory less MCC MCC enhancement Mucociliary clearance Patient patients treated patients with COVID-19 per-protocol Placebo PPS Prospective randomised recruitment required respiratory respiratory diseases Safety Shortness of breath. significant effect supplemental oxygen the placebo group therapy treat treating COVID-19 Trial [DOI] 10.1007/s12325-022-02135-z PMC 바로가기 [Article Type] Randomized Controlled Trial
Risk factors for hospitalisation and death from COVID-19: a prospective cohort study in South Sudan and Eastern Democratic Republic of the CongoObservational Study Published on 2022-05-182022-10-04 Journal: BMJ Open [Category] 임상, [키워드] 95% CI adjusted AOR Care Characteristics Cohort Comorbidities Comorbidity COVID-19 COVID-19 cases death deaths demographic demographic characteristics described discharge effective eligible enrolled enrolment Epidemiology evaluate evaluated Evidence Factor FIVE greater Health higher odd hospitalisation hospitalised increased mortality individual Malnutrition Mortality North occurred Older age Outpatient oxygen Oxygen level Presence presenting progression Prospective prospective cohort study Public public health questionnaire regression models respiratory symptom risk factor significantly South SSD Symptom symptomatic individuals Symptoms [DOI] 10.1136/bmjopen-2021-060639 PMC 바로가기 [Article Type] Observational Study
Study protocol to test the efficacy of self-administration of dexmedetomidine sedative therapy on anxiety, delirium, and ventilator days in critically ill mechanically ventilated patients: an open-label randomized clinical trial중환자 기계 환기 환자의 불안, 섬망 및 인공 호흡기 일에 대한 덱스메데토미딘 진정 요법의 자가 투여 효과를 테스트하기 위한 연구 프로토콜: 공개 라벨 무작위 임상 시험Article Published on 2022-05-162022-09-11 Journal: Trials [Category] 임상, [키워드] addition aggregate alertness alleviate alteration Anxiety approach approaches assigned Care change clinical Clinical practice clinical trial Consistency Course COVID-19 case COVID-19 pandemic Critically ill delirium Depression dexmedetomidine distress Efficacy eligible Eligible participants eligible patient Eligible patients enrolment equipment extubation finding flexible functional Functional status healthcare ICU ICU care ICU patient ICU Patients identify impacted imperative intensive care intensive care unit life management Mechanical mechanical ventilation mechanical ventilatory support mechanically ventilated mechanically ventilated patient mechanically ventilated patients medication Open-label opioid outcome Oxygenation Pain Patient patient symptom Patient symptoms physical Post-traumatic stress disorder Protective protocol Psychological well-being Quality of life randomization Randomized randomized clinical trial Randomly receiving recruitment Secondary objective Secondary objectives Sedation sedative Self-management Side effects significantly study population subset Symptom therapy Trial trial enrolment usual care ventilator ventilator-free day Ventilator-free days ventilatory support [DOI] 10.1186/s13063-022-06391-w PMC 바로가기 [Article Type] Article
Long-term cardio-vascular risk assessment in chronic kidney disease and kidney transplanted patients following SARS-COV-2 disease: protocol for multi-center observational match controlled trial만성 신장 질환 및 SARS-COV-2 질환에 따른 신장 이식 환자의 장기 심혈관 위험 평가: 다기관 관찰 일치 대조 시험 프로토콜Article Published on 2022-05-062022-09-11 Journal: BMC Nephrology [Category] COVID19(2023년), SARS, 임상, [키워드] Acute kidney injury acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affecting angiotensin Angiotensin-converting enzyme association binding Biomarkers blood vessels Cardiac complications Cardio-vascular risk cardiovascular cardiovascular disease caused chronic Chronic kidney disease CKD clinical evaluation control group Controlled trial coronavirus coronavirus disease COVID-19 COVID-19 disease CVD database de novo death determine dialysis disease echocardiographic parameters Endothelial cell endothelial cells Endothelial dysfunction enrolment epithelial cells expected expressed focus heart higher risk implication incidence investigator investigators kidney Kidney disease kidney transplant lung mechanism multi-organ failure outcomes pandemic Patient patients pericyte pericytes podocyte produced protocol proximal pulse Pulse wave pulse wave velocity Registered renal risk risk factor SARS-CoV-2 SARS-COV-2 infection Sepsis severe acute respiratory syndrome Coronavirus severe disease Shock the disease therapeutic options Trial worse prognosis [DOI] 10.1186/s12882-022-02809-4 PMC 바로가기 [Article Type] Article
Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial고위험 비-ST 상승 심근경색증에서 초기 침습성 혈관조영술과 표준 치료 비교: 전향적 다기관 무작위 대조 RAPID N-STEMI 시험을 위한 연구 프로토콜Article Published on 2022-05-032022-09-11 Journal: BMJ Open [Category] 임상, [키워드] all-cause mortality Analysis approved bleeding Cambridge Clinical outcome clinical outcomes completion Coronary coronary angiography Coronary heart disease coronary intervention COVID-19 pandemic defined determine East East of England England enrolled enrolment Ethics ethics committee event event rates expected heart disease heart failure Hospital admission Hypothesis IMPROVE include Infarct invasive Ischaemic heart disease major bleeding mechanistic data multicentre Myocardial Myocardial infarction Neutral Open-label participant Patient patients Percutaneous coronary intervention Pragmatic Primary outcome proportion randomised randomised controlled recommendation registration number registry Research Ethics retrospective secondary outcome Sponsor Standard of care stroke Study protocol submitted Trial trials within 6 months [DOI] 10.1136/bmjopen-2021-055878 PMC 바로가기 [Article Type] Article
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trialCOVID-19(TICO)로 입원한 성인을 위한 두 가지 중화 단일클론항체 치료제인 소트로비맙과 BRII-196과 BRII-198의 효능 및 안전성: 무작위 대조 시험Randomized Controlled Trial Published on 2022-05-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] addition adjusted adjusted odds ratio Administered analyses Analysis assigned Biotechnology Clinical outcome clinical recovery clinical trial Complication complications of COVID-19 COVID-19 COVID-19 symptom death defined Denmark died discharge double-blind Efficacy Efficacy and safety eligible enrolled enrolment female hospital hospitalised Inpatient Interim intravenously laboratory-confirmed SARS-CoV-2 infection male matching placebo median age modified intention-to-treat monoclonal antibody neutralising operation Organ failure outcome participant Patient Placebo placebo group placebo-controlled Poland Primary outcome randomisation randomised randomised controlled trial Randomly recruited Registered Serious Adverse Events significantly higher single dose speed Standard of care stratified study drug sustained Switzerland the placebo group Therapeutics Therapies therapy Treatment Trial USA were assessed with COVID-19 [DOI] 10.1016/S1473-3099(21)00751-9 PMC 바로가기 [Article Type] Randomized Controlled Trial